跳至主要内容
临床试验/NCT04123990
NCT04123990Unknown不适用

Study of the Prevalence of Iron Deficiency in Patients With Chronic Inflammatory Bowel Disease

VIFORFRANCE0 个研究点目标入组 1,100 人开始时间: 2019年11月2日最近更新:
适应症
干预措施

试验速览

阶段
不适用
发起方
入组人数
1,100
主要终点
Ferritinemia according to inflammatory status

研究概览

简要总结

Despite its known prevalence in IBD, a recent study conducted with Prof. Cacoub (unpublished) on the national health insurance database showed that iron deficiency was an under-diagnosed and under-treated co-morbidity. In chronic diseases including IBD, Transferrin Saturation Factor is only performed in approximately 10% of cases, whereas it is recommended in inflammatory situations including IBD patients (HAS 2011).

The objective of this study is therefore to obtain updated French data on the prevalence of iron deficiency in patients with IBD by applying the recommendations of ECCO and French Health High Authority (determination of ferritinemia and Transferrin Saturation Factor)

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient, male or female, over 18 years old
  • Patient present at the hospital on the day of the study
  • Diagnosis of IBD on international criteria
  • Patient giving written consent

排除标准

  • Protected patient: major under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision;
  • pregnant, lactating or parturient woman;
  • Patient hospitalized without consent

研究组 & 干预措施

IBD

Experimental

干预措施: Iron status testing (Diagnostic Test)

结局指标

主要结局

Ferritinemia according to inflammatory status

时间窗: One day

Ferritinemia will be assessed from blood sample (iron status)

次要结局

未报告次要终点

研究者

发起方
VIFORFRANCE
申办方类型
Industry
责任方
Sponsor

相似试验